HUTCHMED Highlights Data to be Presented at ASCO

Summary by AI BETAClose X

HUTCHMED announced that new and updated clinical data for its compounds savolitinib, fruquintinib, and surufatinib will be presented at the 2026 ASCO Annual Meeting. Notably, the pivotal Phase II registration study of savolitinib in MET-amplified gastric cancer met its primary endpoint with an objective response rate of 32.3%, supporting its New Drug Application submission in China. Additional presentations will cover fruquintinib's performance in colorectal and renal cell carcinoma studies, as well as investigator-initiated studies across various tumor indications, alongside surufatinib data in ovarian cancer and thymic epithelial tumors.

Disclaimer*

UK 100

Latest directors dealings